QIANSHAN TAO#, QING ZHANG#, HUIPING WANG, HAO XIAO, MEI ZHOU, LINLIN LIU, HUI QIN, JIYU WANG, FURUN AN, ZHIMIN ZHAI*, YI DONG*
BIOCELL, Vol.46, No.1, pp. 159-169, 2022, DOI:10.32604/biocell.2021.014139
Abstract Acute myeloid leukemia (AML) is regarded as a stem cell disease. However, no one unique marker is expressed
on leukemia stem cells (LSC) but not on leukemic blasts nor normal hematopoietic stem cells (HSC). CD34+
CD38- with
or without CD123 or CD44 subpopulations are immunophenotypically defined as putative LSC fractions in AML.
Nevertheless, markers that can be effectively and simply held responsible for the intrinsical heterogeneity of LSC is
still unclear. In the present study, we examined the frequency of three different LSC subtypes (CD34+
CD38-,
CD34+
CD38-
CD123+
, CD34+
CD38-
CD44+
) in AML at diagnosis. We then… More >
Login
Register
